Health ❯ Mental Health ❯ Depression

Treatment-Resistant Depression

Clinical Trials Ketamine Ketamine Therapy Ketogenic Diet Psychedelic Therapy Esketamine Nasal Spray Treatments Investigational Drugs Psilocybin Immunotherapy

3 ARTICLES

23h ago

Lilly Expands Neuroscience Pipeline With $2.8 Billion Purchase of AtaiBeckley

The cash deal brings an investigational treatment‑resistant depression drug into Lilly’s lineup and signals a deliberate move to diversify beyond its GLP‑1 weight‑loss franchise.

Stories older than 24h

4 ARTICLES

last wk.

Lilly to Acquire AtaiBeckley in Deal Valued Up to $3.8 Billion

6 ARTICLES

2mo ago

IL‑6 Blocker Tocilizumab Shows Early Promise for Inflammation‑Linked Depression

3 ARTICLES

3mo ago

FDA Clears Motif Neurotech Trial of At-Home Brain Implant for Treatment-Resistant Depression

4 ARTICLES

5mo ago

Psilocybin Therapy Clears Second Phase 3 Test as Compass Pathways Preps FDA Bid

5 ARTICLES

5mo ago

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

3 ARTICLES

5mo ago

Ketogenic Diet Yields Modest Six‑Week Relief in Drug‑Resistant Depression

4 ARTICLES

5mo ago

Small Trial Finds Short-Term Antidepressant Effect From Ketogenic Diet in Treatment-Resistant Depression

6 ARTICLES

8mo ago

Meta-Analysis Finds Nitrous Oxide Offers Rapid, Short-Lived Relief for Depression

3 ARTICLES

10mo ago

IV Ketamine Shows Faster, Larger Gains Than Esketamine Nasal Spray in New Real‑World Depression Study

3 ARTICLES

last yr.

New Zealand Greenlights Restricted Psilocybin Therapy for Treatment-Resistant Depression

6 ARTICLES

last yr.

Classical Music Shows Promise in Treating Depression Through Brain Synchronization

10 ARTICLES

2y ago

Ketamine Shows Promise for Treatment-Resistant Depression in Clinical Trials

4 ARTICLES

2y ago

Treatment-Resistant Depression

Lilly Expands Neuroscience Pipeline With $2.8 Billion Purchase of AtaiBeckley

Lilly to Acquire AtaiBeckley in Deal Valued Up to $3.8 Billion

IL‑6 Blocker Tocilizumab Shows Early Promise for Inflammation‑Linked Depression

FDA Clears Motif Neurotech Trial of At-Home Brain Implant for Treatment-Resistant Depression

Psilocybin Therapy Clears Second Phase 3 Test as Compass Pathways Preps FDA Bid

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Ketogenic Diet Yields Modest Six‑Week Relief in Drug‑Resistant Depression

Small Trial Finds Short-Term Antidepressant Effect From Ketogenic Diet in Treatment-Resistant Depression

Meta-Analysis Finds Nitrous Oxide Offers Rapid, Short-Lived Relief for Depression

IV Ketamine Shows Faster, Larger Gains Than Esketamine Nasal Spray in New Real‑World Depression Study

Never miss stories about

Treatment-Resistant Depression

New Zealand Greenlights Restricted Psilocybin Therapy for Treatment-Resistant Depression

Australia Subsidizes Esketamine Spray for Treatment-Resistant Depression

FDA Approves First Standalone Nasal Spray for Treatment-Resistant Depression

FDA Approves First Nasal Spray for Treatment-Resistant Depression

Vagus Nerve Stimulation Shows Promise for Severe Depression Treatment

Classical Music Shows Promise in Treating Depression Through Brain Synchronization

Ketamine Shows Promise for Treatment-Resistant Depression in Clinical Trials

Matthew Perry's Death Sparks Debate on Ketamine Use

Never miss stories about

Treatment-Resistant Depression